Pharmaceutical partnership
Appears in 1 story
Developer of the approved rival Enhertu
BioNTech and DualityBio's Phase 3 breast cancer trial met its main goal, but the result is muted. Trastuzumab pamirtecan improved progression-free survival over chemotherapy in 541 patients with hormone receptor-positive, HER2-low metastatic breast cancer. The companies call the gain "statistically significant, yet modest."
Updated 3 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
